We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Argenta Expands Collaboration with Genentech to Include BioFocus

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute
Argenta, a service division of Galapagos NV, has announced it has signed a contract extension with Genentech, Inc., a member of the Roche Group. The extended agreement expands the portfolio of projects which are in collaboration with Genentech and allows Genentech to place projects directly into Galapagos’ other service division, BioFocus.

Argenta’s collaboration with Genentech dates back to 2005. The current agreement covers a number of drug discovery programs that utilize Argenta's expertise in computer-aided drug design (CADD), medicinal chemistry, and in vitro biology and screening to discover new chemical entities acting against undisclosed drug targets defined by Genentech. Under the amendment, BioFocus will provide Genentech with integrated medicinal chemistry, in vitro biology and ADME services.

“We are delighted that Genentech has expanded its small-molecule drug discovery outsourcing into BioFocus, and we regard it as testament to the complementary expertise and technological capabilities that Argenta and BioFocus possess,” said Chris Newton, Senior Vice President, Galapagos Services.